All AbMole products are for research use only, cannot be used for human consumption.
Fimepinostat (CUDC-907) is an orally-available small molecule inhibitor that targets both HDAC and PI3K with IC50 values of 19 nM, 54 nM, 311 nM and 39 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ respectively. Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes. Fimepinostat (CUDC-907) durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling molecules such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases. Fimepinostat (CUDC-907) shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.
 |
Source | Stem Cells Dev (2017). Figure 3. CUDC-907 |
| Method | Western blot | |
| Cell Lines | H3K9ac, H4K8ac, H3K4me2 cell | |
| Concentrations | 500 nM | |
| Incubation Time | 24 h | |
| Results | Interestingly, the combination of both HDAC and PI3K inhibitors failed to induce adipogenesis, suggesting additional possible mechanism by which CUDC-907 promotes adipogenesis |
 |
Source | Stem Cells Dev (2017). Figure 1. CUDC-907 |
| Method | Adipogenic differentiation | |
| Cell Lines | hMSCs | |
| Concentrations | 500 nM | |
| Incubation Time | 24 h | |
| Results | CUDC-907 treatment of hBMSCs enhanced adipocyte differentiation, as evidenced by the greater Oil Red O staining and quantitative analysis demonstrated that the number of mature adipocytes identified by Nile red staining was higher. |
| Cell Experiment | |
|---|---|
| Cell lines | BT474, N87, H1975, H1993, Calu-6, H460 cells line |
| Preparation method | Cancer cell growth inhibition assay Human cancer cell lines were purchased from American Type Culture Collection (Manassas, VA) and plated at densities of 5,000 to 10,000 per well in 96-well flat-bottomed plates with the recommended culture medium. The cells were then incubated with compounds at various concentrations for 72 hours in culture medium supplemented with 0.5% (v/v) FBS. Growth inhibition was assessed by assay of cellular ATP content using the Perkin-Elmer ATPlite kit. |
| Concentrations | 0~900nM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Six- to 8-week-old female athymic (nude nu/nu CD-1) or severe combined immunodeficient (SCID) mice Daudi NHL xenograft mouse model |
| Formulation | formulated in 30% Captisol |
| Dosages | 25, 50, and 100 mg/kg |
| Administration | oral gavage |
| Molecular Weight | 508.55 |
| Formula | C23H24N8O4S |
| CAS Number | 1339928-25-4 |
| Solubility (25°C) | DMSO 52 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related HDAC Products |
|---|
| CM-444
CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models. |
| CM-1758
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells. |
| T-518
T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6. |
| SE-7552
SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. |
| BRD9757
BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
